CTCX (Carmell Corporation) Short-Term Debt to Capital

Corporate company logo of Carmell Corporation (CTCX)

Carmell Corporation dominates the cosmeceutical niche thanks to its exclusive PBAF extraction technology for epidermal regeneration. The company generates revenue by supplying innovative plasma materials to surgery and aesthetic medicine. Business stability is guaranteed by an autonomous product cycle that remains independent of global crises. This market trend, visualized in monetary terms, confirms these data, with the indicator standing at 0.00.

Ratio of Short-Term Indebtedness to Capital: Carmell Corp (CTCX) for 02/21/2024 - 03/10/2025

Analytical breakdowns for Carmell Corporation

- stock quotes and analyst forecast:
Stock Price Carmell Corp|CTCX - Fair Value Consensus
- business market valuation indicators:
Market Capitalization Carmell Corp.|CTCX - Enterprise Value
- book capitalization information:
Net Assets per Single Share Carmell|CTCX - Accounting Value of Company|Market Value to Book Value Ratio carmellrx.com|CTCX - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Carmell Corporation|CTCX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Carmell|CTCX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Carmell Corp.|CTCX - Company Long-Term Liabilities|Company Short-Term Debts Carmell|Quick Liquidity Indicator carmellrx.com
- company profitability and valuation multiples indicators:
CTCX - Profit After Payment of Taxes
Fundamental valuation:CTCX Carmell Corp
Brand item of Carmell Corp.

To assess the financial stability of Carmell Corporation (CTCX), it is critical to monitor the share of short-term liabilities within the equity structure, which allows for the measurement of the current burden of urgent debt on liquidity. By analyzing the history of short-term accounts payable relative to equity, an investor can see how Carmell Corporation balances R&D expenditures with efficient production outsourcing to maintain high margins during global scaling.

Competitors of Carmell Corporation

Short-Term Debt to Capital ASND|MDGL (Madrigal Corp) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital CORT (Corcept Therapeutics)|Short-Term Debt to Capital rhythmtx.com RYTM|AKRO - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital MTSR (Metsera, Inc.)|MoonLake Pharma (MLTX) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Crinetics Corp|NAMS (NewAmsterdam Pharma) - Short-Term Debt to Capital|Short-Term Debt to Capital soleno.life|Short-Term Debt to Equity Ratio FOLD (Amicus Therapeutics, Inc.)|ETNB (89bio Inc) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Agios Pharmaceuticals Inc AGIO|GPCR - Short-Term Debt to Equity Ratio|MiMedx Group, Inc. - Short-Term Debt to Capital|Current Liabilities to Capital rezolutebio.com|LXRX (Lexicon Pharmaceuticals, Inc.) - Short-Term Debt to Equity Ratio|MBX: Short-Term Loans to Capital Ratio|ALT (Altimmune Corp) - Short-Term Debt to Capital|Short-Term Debt to Capital Aardvark Pharma|Short-Term Debt to Capital SGMT|Short-Term Debt to Equity BIOA (bioagelabs.com)|Short-Term Debt to Equity Biomea Fusion BMEA|Quince Therapeutics Inc (QNCX) - Current Liabilities to Capital|GUTS - Short-Term Debt to Equity|VTVT: Short-Term Debt to Equity|ATPC: Short-Term Debt to Capital|PLUR - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Synlogic Inc.|Lipocine Inc (LPCN) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Matinas BioPharma (MTNB)|Short-Term Debt to Equity Ratio sprucebiosciences.com SPRB|Short-Term Debt to Capital GLTO (Galecto, Inc.)|LUMO - Short-Term Debt to Equity Ratio|Organovo - Short-Term Debt to Capital|RDUS - Short-Term Debt to Capital